vs
BIODESIX INC（BDSX）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是BIODESIX INC的1.7倍（$50.3M vs $28.8M），READING INTERNATIONAL INC净利率更高（-5.1% vs -13.8%，领先8.7%），BIODESIX INC同比增速更快（40.8% vs -14.2%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $692.0K），过去两年BIODESIX INC的营收复合增速更高（39.3% vs 5.6%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
BDSX vs RDI — 直观对比
营收规模更大
RDI
是对方的1.7倍
$28.8M
营收增速更快
BDSX
高出54.9%
-14.2%
净利率更高
RDI
高出8.7%
-13.8%
自由现金流更多
RDI
多$3.4M
$692.0K
两年增速更快
BDSX
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $50.3M |
| 净利润 | $-4.0M | $-2.6M |
| 毛利率 | — | — |
| 营业利润率 | -6.8% | -1.9% |
| 净利率 | -13.8% | -5.1% |
| 营收同比 | 40.8% | -14.2% |
| 净利润同比 | 51.8% | -14.5% |
| 每股收益（稀释后） | $-3.35 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXRDI
| Q4 25 | $28.8M | $50.3M | ||
| Q3 25 | $21.8M | $52.2M | ||
| Q2 25 | $20.0M | $60.4M | ||
| Q1 25 | $18.0M | $40.2M | ||
| Q4 24 | $20.4M | $58.6M | ||
| Q3 24 | $18.2M | $60.1M | ||
| Q2 24 | $17.9M | $46.8M | ||
| Q1 24 | $14.8M | $45.1M |
净利润BDSXRDI
| Q4 25 | $-4.0M | $-2.6M | ||
| Q3 25 | $-8.7M | $-4.2M | ||
| Q2 25 | $-11.5M | $-2.7M | ||
| Q1 25 | $-11.1M | $-4.8M | ||
| Q4 24 | $-8.3M | $-2.2M | ||
| Q3 24 | $-10.3M | $-7.0M | ||
| Q2 24 | $-10.8M | $-12.8M | ||
| Q1 24 | $-13.6M | $-13.2M |
营业利润率BDSXRDI
| Q4 25 | -6.8% | -1.9% | ||
| Q3 25 | -32.4% | -0.6% | ||
| Q2 25 | -48.6% | 4.8% | ||
| Q1 25 | -50.9% | -17.2% | ||
| Q4 24 | -32.5% | 2.6% | ||
| Q3 24 | -47.3% | -0.6% | ||
| Q2 24 | -46.0% | -16.4% | ||
| Q1 24 | -74.4% | -16.7% |
净利率BDSXRDI
| Q4 25 | -13.8% | -5.1% | ||
| Q3 25 | -40.0% | -8.0% | ||
| Q2 25 | -57.3% | -4.4% | ||
| Q1 25 | -61.8% | -11.8% | ||
| Q4 24 | -40.4% | -3.8% | ||
| Q3 24 | -56.5% | -11.7% | ||
| Q2 24 | -60.3% | -27.4% | ||
| Q1 24 | -91.9% | -29.4% |
每股收益（稀释后）BDSXRDI
| Q4 25 | $-3.35 | $-0.11 | ||
| Q3 25 | $-1.16 | $-0.18 | ||
| Q2 25 | $-0.08 | $-0.12 | ||
| Q1 25 | $-0.08 | $-0.21 | ||
| Q4 24 | $-5.02 | $-0.11 | ||
| Q3 24 | $-1.40 | $-0.31 | ||
| Q2 24 | $-0.08 | $-0.57 | ||
| Q1 24 | $-0.14 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $10.5M |
| 总债务越低越好 | $50.0M | $185.1M |
| 股东权益账面价值 | $-2.5M | $-18.2M |
| 总资产 | $87.5M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDSXRDI
| Q4 25 | $19.0M | $10.5M | ||
| Q3 25 | $16.6M | $8.1M | ||
| Q2 25 | $20.7M | $9.1M | ||
| Q1 25 | $17.6M | $5.9M | ||
| Q4 24 | $26.2M | $12.4M | ||
| Q3 24 | $31.4M | $10.1M | ||
| Q2 24 | $42.2M | $9.3M | ||
| Q1 24 | $11.5M | $7.5M |
总债务BDSXRDI
| Q4 25 | $50.0M | $185.1M | ||
| Q3 25 | $50.0M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | $202.7M | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.1M | — | ||
| Q1 24 | $40.1M | — |
股东权益BDSXRDI
| Q4 25 | $-2.5M | $-18.2M | ||
| Q3 25 | $-1.7M | $-12.1M | ||
| Q2 25 | $1.1M | $-7.7M | ||
| Q1 25 | $11.1M | $-8.1M | ||
| Q4 24 | $20.9M | $-4.4M | ||
| Q3 24 | $27.9M | $1.6M | ||
| Q2 24 | $36.3M | $6.5M | ||
| Q1 24 | $-5.5M | $18.0M |
总资产BDSXRDI
| Q4 25 | $87.5M | $434.9M | ||
| Q3 25 | $88.7M | $435.2M | ||
| Q2 25 | $87.7M | $438.1M | ||
| Q1 25 | $86.2M | $441.0M | ||
| Q4 24 | $97.2M | $471.0M | ||
| Q3 24 | $102.7M | $495.7M | ||
| Q2 24 | $115.8M | $494.9M | ||
| Q1 24 | $87.2M | $494.9M |
负债/权益比BDSXRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | $4.1M |
| 自由现金流率自由现金流/营收 | 2.4% | 8.2% |
| 资本支出强度资本支出/营收 | 0.3% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-23.5M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流BDSXRDI
| Q4 25 | $778.0K | $4.3M | ||
| Q3 25 | $-8.9M | $295.0K | ||
| Q2 25 | $-6.6M | $1.6M | ||
| Q1 25 | $-8.6M | $-7.7M | ||
| Q4 24 | $-4.1M | $8.0M | ||
| Q3 24 | $-10.7M | $1.3M | ||
| Q2 24 | $-18.6M | $-10.4M | ||
| Q1 24 | $-15.3M | $-2.8M |
自由现金流BDSXRDI
| Q4 25 | $692.0K | $4.1M | ||
| Q3 25 | $-8.9M | $-246.0K | ||
| Q2 25 | $-6.6M | $1.2M | ||
| Q1 25 | $-8.7M | $-8.0M | ||
| Q4 24 | $-4.9M | $7.0M | ||
| Q3 24 | $-10.9M | $-1.1M | ||
| Q2 24 | $-20.5M | $-10.6M | ||
| Q1 24 | $-15.5M | $-4.7M |
自由现金流率BDSXRDI
| Q4 25 | 2.4% | 8.2% | ||
| Q3 25 | -41.0% | -0.5% | ||
| Q2 25 | -33.1% | 1.9% | ||
| Q1 25 | -48.3% | -19.8% | ||
| Q4 24 | -24.2% | 12.0% | ||
| Q3 24 | -60.1% | -1.8% | ||
| Q2 24 | -114.3% | -22.7% | ||
| Q1 24 | -104.9% | -10.4% |
资本支出强度BDSXRDI
| Q4 25 | 0.3% | 0.3% | ||
| Q3 25 | 0.2% | 1.0% | ||
| Q2 25 | 0.3% | 0.6% | ||
| Q1 25 | 0.4% | 0.6% | ||
| Q4 24 | 4.1% | 1.7% | ||
| Q3 24 | 1.3% | 4.0% | ||
| Q2 24 | 10.7% | 0.5% | ||
| Q1 24 | 1.6% | 4.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
